Seeking Opinions on the Use of 2'-Fucosyllactose Produced by Genetically Modified Glutamic Acid Bacillus for Infant Formula

In a recent notification by the Australia New Zealand Food Standards Agency (FSANZ), numbered 282-24, an application under A1283 was made to solicit opinions on the use of 2'-fucosyllactose (2'-FL) produced by genetically modified glutamic acid Bacillus for infant formula. The deadline for submitting opinions is March 22, 2024.

The Australia New Zealand Food Standards Agency (FSANZ) has initiated a public consultation process regarding the use of 2'-fucosyllactose (2'-FL) in infant formula. The agency has received an application, A1283, for the approval of 2'-FL produced by genetically modified glutamic acid Bacillus for use in infant formula. The purpose of this consultation is to gather opinions from stakeholders and the public regarding the safety and suitability of incorporating 2'-FL in infant formula products.

2'-Fucosyllactose is a complex sugar molecule naturally found in human breast milk. It is known to possess prebiotic properties and has been suggested to contribute to the development of a healthy gut microbiome in infants. The use of 2'-FL in infant formula aims to replicate some of the benefits provided by breast milk, offering a potential nutritional advantage to formula-fed infants.

However, the production of 2'-FL involves genetically modified glutamic acid Bacillus. This raises concerns among some stakeholders regarding the safety and ethical implications of using genetically modified organisms (GMOs) in food production. FSANZ recognizes the need to thoroughly assess the potential risks associated with the use of 2'-FL produced by genetically modified strains.

The public consultation process provides an opportunity for experts, industry representatives, and concerned individuals to express their views on the proposed use of 2'-FL in infant formula. FSANZ encourages stakeholders to submit evidence-based opinions, supported by scientific research and relevant data, to facilitate a comprehensive assessment of the safety and suitability of 2'-FL in infant nutrition.

Stakeholders can participate in the consultation process by submitting their opinions and relevant information to FSANZ before the deadline of March 22, 2024, at 6:00 PM Canberra time. The agency will consider all submissions received during this period and evaluate the potential risks and benefits associated with the use of 2'-FL in infant formula.

It is important to note that FSANZ's decision regarding the approval of 2'-FL in infant formula will be based on a thorough evaluation of scientific evidence, risk assessments, and public opinions. The agency's primary objective is to uphold the safety and quality standards of food products while ensuring consumer protection and transparency in the decision-making process.

In conclusion, the FSANZ's call for opinions on the use of 2'-fucosyllactose produced by genetically modified glutamic acid Bacillus in infant formula reflects the agency's commitment to evidence-based decision-making and stakeholder engagement. The consultation process serves as a platform to gather diverse perspectives and scientific insights, ultimately contributing to informed regulatory decisions regarding the use of innovative ingredients in infant nutrition.